Top

Published in:

01-05-2016

Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation

Authors: Sonja Darrell Bartolome, Fernando Torres

Published in: Heart Failure Reviews | Issue 3/2016

Abstract

Severe pulmonary hypertension is recognized by focusing on the clinical signs and tests that demonstrate decompensated right ventricular failure or, in the worst-case scenario, shock. An aggressive treatment regimen including a prostacyclin infusion is required for these patients. Once admitted to the hospital, or the ICU for decompensated right ventricular failure, the short- and long-term outcomes for PAH patients are poor. For those who are candidates, urgent lung transplantation, or extracorporeal membrane oxygenation (ECMO) as a bridge to lung transplantation may be rescue therapy.

Taichman DB, Ornelas J, Chung L et al (2014) Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 146(2):449–475CrossRefPubMedPubMedCentral

McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53(17):1573–1619CrossRefPubMed

Benza RL, Miller DP, Gomberg-Maitland M et al (2010) Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 122(2):164–172CrossRefPubMed

Humbert M, Sitbon O, Chaouat A et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122(2):156–163CrossRefPubMed

McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114(13):1417–1431CrossRefPubMed

Raymond RJ, Hinderliter AL, Willis PW et al (2002) Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39(7):1214–1219CrossRefPubMed

Forfia PR, Fisher MR, Mathai SC et al (2006) Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174(9):1034–1041CrossRefPubMed

Mathai SC, Sibley CT, Forfia PR et al (2011) Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol 38(11):2410–2418CrossRefPubMed

McLaughlin VV, Gaine SP, Howard LS et al (2013) Treatment goals of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D73–D81CrossRefPubMed

10.

van Wolferen SA, Marcus JT, Boonstra A et al (2007) Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28(10):1250–1257CrossRefPubMed

11.

Yamada Y, Okuda S, Kataoka M et al (2012) Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. Circ J 76(7):1737–1743CrossRefPubMed

12.

van de Veerdonk MC, Kind T, Marcus JT et al (2011) Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 58(24):2511–2519CrossRefPubMed

13.

Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M (2010) Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 35(5):1079–1087CrossRefPubMed

14.

Humbert M, Sitbon O, Yaici A et al (2010) Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 36(3):549–555CrossRefPubMed

15.

Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334(5):296–301CrossRefPubMed

16.

Schwaiblmair M, Faul C, von Scheidt W, Berghaus TM (2012) Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension. BMC Pulm Med 12:23CrossRefPubMedPubMedCentral

17.

Wensel R, Opitz CF, Anker SD et al (2002) Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106(3):319–324CrossRefPubMed

18.

Nickel N, Golpon H, Greer M et al (2012) The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 39(3):589–596CrossRefPubMed

19.

Galie N, Humbert M, Vachiery JL et al (2015) ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International society for heart and lung transplantation (ISHLT). Eur Respir J 46(4):903–975CrossRefPubMed

20.

Benza RL, Gomberg-Maitland M, Miller DP et al (2012) The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 141(2):354–362CrossRefPubMed

21.

Campo A, Mathai SC, Le Pavec J et al (2011) Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 38(2):359–367CrossRefPubMed

22.

Haddad F, Peterson T, Fuh E et al (2011) Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail 4(6):692–699CrossRefPubMed

23.

Sztrymf B, Souza R, Bertoletti L et al (2010) Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 35(6):1286–1293CrossRefPubMed

24.

Ghignone M, Girling L, Prewitt RM (1984) Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 60(2):132–135CrossRefPubMed

25.

Zamanian RT, Haddad F, Doyle RL, Weinacker AB (2007) Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 35(9):2037–2050CrossRefPubMed

26.

Tayama E, Ueda T, Shojima T et al (2007) Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact CardioVasc Thorac Surg 6(6):715–719CrossRefPubMed

27.

Price LC, Forrest P, Sodhi V et al (2007) Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth 99(4):552–555CrossRefPubMed

28.

Kerbaul F, Rondelet B, Motte S et al (2004) Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 32(4):1035–1040CrossRefPubMed

29.

Gordon C, Collard CD, Pan W (2010) Intraoperative management of pulmonary hypertension and associated right heart failure. Curr Opin Anaesthesiol 23(1):49–56CrossRefPubMed

30.

Pritts CD, Pearl RG (2010) Anesthesia for patients with pulmonary hypertension. Curr Opin Anaesthesiol 23(3):411–416CrossRefPubMed

31.

Hoeper MM, Granton J (2011) Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med 184(10):1114–1124CrossRefPubMed

32.

Simonneau G, Rubin LJ, Galie N et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149(8):521–530CrossRefPubMed

33.

Sitbon O, Jais X, Savale L et al (2014) Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 43(6):1691–1697CrossRefPubMed

34.

Bhorade S, Christenson J, O’Connor M, Lavoie A, Pohlman A, Hall JB (1999) Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 159(2):571–579CrossRefPubMed

35.

Hardy JD, Webb WR, Dalton ML Jr, Walker GR Jr (1963) Lung homotransplantation in Man. JAMA 186:1065–1074CrossRefPubMed

36.

Reitz BA, Wallwork JL, Hunt SA et al (1982) Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 306(10):557–564CrossRefPubMed

37.

Toronto Lung Transplant Group (1986) Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 314(18):1140–1145CrossRef

38.

Pasque MK, Cooper JD, Kaiser LR, Haydock DA, Triantafillou A, Trulock EP (1990) Improved technique for bilateral lung transplantation: rationale and initial clinical experience. Ann Thorac Surg 49(5):785–791CrossRefPubMed

39.

Yusen RD, Christie JD, Edwards LB et al (2013) The registry of the International Society for heart and lung transplantation: thirtieth adult lung and heart-lung transplant report–2013; focus theme: age. J Heart Lung Transpl 32(10):965–978CrossRef

40.

Yusen RD, Edwards LB, Kucheryavaya AY et al (2014) The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report–2014; focus theme: retransplantation. J Heart Lung Transpl 33(10):1009–1024CrossRef

41.

Paden ML, Conrad SA, Rycus PT, Thiagarajan RR (2013) Extracorporeal life support organization registry report 2012. ASAIO J 59(3):202–210CrossRefPubMed

42.

Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B (2008) Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 17(Suppl 4):S41–S47CrossRefPubMed

43.

Jackson A, Cropper J, Pye R, Junius F, Malouf M, Glanville A (2008) Use of extracorporeal membrane oxygenation as a bridge to primary lung transplant: 3 consecutive, successful cases and a review of the literature. J Heart Lung Transpl 27(3):348–352CrossRef

44.

Santambrogio L, Nosotti M, Palleschi A et al (2009) Use of venovenous extracorporeal membrane oxygenation as a bridge to urgent lung transplantation in a case of acute respiratory failure. Transpl Proc 41(4):1345–1346CrossRef

45.

Gibbon JH Jr (1954) Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 37(3):171–185PubMed

46.

Hill JD, O’Brien TG, Murray JJ et al (1972) Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. N Engl J Med 286(12):629–634CrossRefPubMed

47.

Bartlett RH, Roloff DW, Custer JR, Younger JG, Hirschl RB (2000) Extracorporeal life support: the University of Michigan experience. JAMA 283(7):904–908CrossRefPubMed

48.

Hoopes CW, Gurley JC, Zwischenberger JB, Diaz-Guzman E (2012) Mechanical support for pulmonary veno-occlusive disease: combined atrial septostomy and venovenous extracorporeal membrane oxygenation. Semin Thorac Cardiovasc Surg 24(3):232–234CrossRefPubMed

Title: Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation
Authors: Sonja Darrell Bartolome
Fernando Torres
Publication date: 01-05-2016
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 3/2016
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-016-9562-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Classification and diagnosis of pulmonary hypertension

Molecular pathogenesis and current pathology of pulmonary hypertension

Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction

Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure

Pulmonary hypertension associated with lung diseases and hypoxemia

Definition, epidemiology and registries of pulmonary hypertension

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page